289 related articles for article (PubMed ID: 34504268)
1. Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops.
Kim M; Jang H; Rho S
Sci Rep; 2021 Sep; 11(1):17896. PubMed ID: 34504268
[TBL] [Abstract][Full Text] [Related]
2. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
4. [In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T)].
Nagai N; Murao T; Oe K; Ito Y; Okamoto N; Shimomura Y
Yakugaku Zasshi; 2011; 131(6):985-91. PubMed ID: 21628988
[TBL] [Abstract][Full Text] [Related]
5. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
6. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
Heijl A; Strahlman E; Sverrisson T; Brinchman-Hansen O; Puustjärvi T; Tipping R
Ophthalmology; 1997 Jan; 104(1):137-42. PubMed ID: 9022118
[TBL] [Abstract][Full Text] [Related]
7. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs.
Inoue K; Shiokawa M; Sugahara M; Wakakura M; Soeda S; Tomita G
Jpn J Ophthalmol; 2012 Nov; 56(6):559-63. PubMed ID: 23001284
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.
Shedden A; Adamsons IA; Getson AJ; Laurence JK; Lines CR; Hewitt DJ; Ho TW
Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1757-64. PubMed ID: 20437244
[TBL] [Abstract][Full Text] [Related]
10. Allergic contact dermatitis from timolol and dorzolamide eye drops.
Kalavala M; Statham BN
Contact Dermatitis; 2006 Jun; 54(6):345. PubMed ID: 16787459
[No Abstract] [Full Text] [Related]
11. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
Martínez A; Sánchez M
Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride.
Ayaki M; Iwasawa A; Niwano Y
Biocontrol Sci; 2012; 17(3):115-20. PubMed ID: 23007102
[TBL] [Abstract][Full Text] [Related]
13. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Michaud JE; Friren B;
Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
[TBL] [Abstract][Full Text] [Related]
14. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction.
Beckers HJ; Schouten JS; Webers CA; van der Valk R; Hendrikse F
Graefes Arch Clin Exp Ophthalmol; 2008 Oct; 246(10):1485-90. PubMed ID: 18575878
[TBL] [Abstract][Full Text] [Related]
15. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma.
Lorenz K; Wasielica-Poslednik J; Bell K; Renieri G; Keicher A; Ruckes C; Pfeiffer N; Thieme H
PLoS One; 2017; 12(2):e0171636. PubMed ID: 28199397
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
[TBL] [Abstract][Full Text] [Related]
18. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
20. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
Chan K; Testa M; McCluskey P
J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
